- Trial phase
- Phase 3 (registrational for PTCL); Phase 2 (atopic dermatitis, ALPS); Phase 1b (hidradenitis suppurativa)
- Time to market
- If the Phase 3 PTCL trial succeeds at its interim futility analysis (Q1 2027) and final readout (estimated primary completion November 2027), a potential NDA submission could occur in 2028, with FDA approval possible in 2029 at the earliest. The atopic dermatitis program is earlier-stage (Phase 2 topline in Q3 2027) and would require additional Phase 3 trials before any regulatory submission.
- Why 7/10
- The next hard, dated catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months from today). Soquelitinib is Corvus's only clinical-stage asset and drives essentially the entire investment thesis, making this a high-impact binary event. The impact score of 7 reflects that this is an interim futility analysis (not a final efficacy readout or PDUFA) on a single-asset company, with the catalyst within ~6 months.
The next major binary catalyst is the Phase 3 PTCL interim futility analysis expected in Q1 2027 (roughly 2-5 months away). A positive result would validate soquelitinib's novel ITK-inhibitor mechanism in oncology and support continued enrollment toward the primary completion in late 2027. A futility stop would severely damage the thesis. Separately, the SIERRA1 atopic dermatitis Phase 2 topline data in Q3 2027 will test the drug's potential in a large immunology market. The ASH 2026 poster (Dec 14) on ALPS data (n=3) is an early readout with limited stock-moving potential.
Price Chart
Executive Summary
Soquelitinib (CPI-818) is Corvus Pharmaceuticals' lead and only clinical-stage asset, an oral, first-in-class selective ITK inhibitor being developed for T-cell lymphoma and immune-inflammatory diseases. The drug has shown promising Phase 1/1b data in relapsed/refractory peripheral T-cell lymphoma (PTCL) with a 37.5% ORR and 28.1-month median OS, published in the journal Blood. A registrational Phase 3 PTCL trial (NCT06561048, n=150) is enrolling with an interim futility analysis expected in Q1 2027. The drug is also being tested in a Phase 2 atopic dermatitis trial (SIERRA1, topline Q3 2027), a Phase 2 ALPS trial (ASH presentation Dec 14, 2026), and a Phase 1b hidradenitis suppurativa trial. Corvus has $202.9 million in cash (Q3 2026), funding operations into Q2 2028. Analyst consensus is Strong Buy with a mean price target of $31.50, but the stock trades at $9.73, reflecting the binary risk of the upcoming Phase 3 interim analysis and the long wait for data readouts.
How It Works
Soquelitinib is an oral pill that selectively blocks an enzyme called ITK (interleukin-2-inducible T-cell kinase), which is found mainly in T-cells, a type of immune cell. By inhibiting ITK, the drug shifts the immune system away from inflammatory responses (Th2 and Th17 pathways) and toward a more balanced, anti-tumor immune state (Th1 skewing). This makes it potentially useful for both T-cell cancers (where it helps the immune system attack cancer cells) and inflammatory diseases like eczema (atopic dermatitis), where it dampens the overactive immune response.
Trial Status
The registrational Phase 3 PTCL trial (NCT06561048) began enrollment in October 2024, targeting 150 patients across 34 sites, with an interim futility analysis expected in Q1 2027 and primary completion estimated in November 2027. The Phase 2 SIERRA1 atopic dermatitis trial (NCT07441395) began enrollment in early 2026 with 200 target patients, topline data expected Q3 2027. A Phase 2 ALPS trial (NIAID-led) has enrolled 3 patients with one-year data to be presented at ASH December 2026. A Phase 1b hidradenitis suppurativa trial is enrolling with initial data expected 1H 2027. Partner Angel Pharmaceuticals completed cohort 1 enrollment in a Phase 1b/2 atopic dermatitis trial in China, with topline data anticipated March 2027.
The Two-Sided Case
Upcoming Catalysts
- ASH 2026 Annual Meeting (Dec 14, 2026): Poster presentation of initial Phase 2 ALPS data (n=3, one-year follow-up)
- Q1 2027: Phase 3 PTCL interim futility analysis - a binary readout that could stop or continue the registrational trial
- March 2027: Angel Pharma (China partner) Phase 1b/2 atopic dermatitis topline data
- 1H 2027: Phase 1b hidradenitis suppurativa initial data
- Q3 2027: SIERRA1 Phase 2 atopic dermatitis topline data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Corvus Pharmaceuticals, Inc. Press Release CRVS ·Originating report